

Matsumoto et al.
U.S.S.N. 09/868,885
Amendment
Page 4

REMARKS

The Applicants appreciate the Examiner's thorough examination of the subject application. Applicants request reconsideration of the subject application based on the following remarks.

Claims 1-12 and 14 stand cancelled without prejudice, claim 13 has been amended, and new claim 17 has been added. Claims 13 and 15-17 are currently pending in the application.

No new matter is presented by virtue of the within amendment. For instance, claim 13, as amended, is supported by the description at page 10, lines 10-17, and page 8, lines 23-27. Similarly, the subject matter of new claim 17 is supported by the description at page 34, line 24 through page 35, line 5, or more specifically on page 35, line 9 through page 36, line 16 of the specification as originally filed.

Claims 13-16 were rejected under 35 USC 112, 1st paragraph, allegedly because the specification, while being enabling for a method of regulating oxytocin secretion as disclosed in base claim 13, by administering oxytocin secretion regulator, comprising a ligand peptide which has the amino acid sequence represented by SEQ ID NO: 3, SEQ ID NO:18, SEQ ID NO:32, SEQ ID NO: 44, or a salt thereof, for G protein-coupled receptors phGR3, does not reasonably provide enablement for other oxytocin secretion regulators.

Although applicants respectfully disagree with the position taken by the examiner, claim 13 has been amended to provide methods of regulating oxytocin secretion comprising administering oxytocin secretion regulator, comprising a ligand peptide which has the amino acid sequence represented by SEQ ID NO: 44.

Matsumoto et al.
U.S.S.N. 09/868,885
Amendment
Page 5


Applicants reserve the right to pursue the subject matter cancelled from claim 13 as originally presented in this or a subsequent application and upon representment address the instant rejection under §112, first paragraph.

Thus, claims 13, 15, and 16, as presently amended, are in full compliance with 35 U.S.C. §112, including the enablement requirement of §112, first paragraph. Thus, the rejection should be withdrawn.

It is believed the application is in condition for immediate allowance, which action is earnestly solicited.

Although it is not believed that any additional fees are needed to consider this submission, the Examiner is hereby authorized to charge our deposit account no. 04-1105 should any fee be deemed necessary.

Respectfully submitted,



Date: March, 2005

John B. Alexander, Ph.D. (Reg. 48,399)
Christine C. O'Day (Reg. 38,256)
EDWARDS & ANGELL, LLP
P.O. Box 55874
Boston, MA 02205
Tel. (617) 439-4444

BOS2_482864.1